DCM
TERN

Driehaus Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Driehaus Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-763,486
Closed -$2.11M – 501
2025
Q1 		$2.11M Sell
763,486
-898,360
-54% -$3.67M 0.02% 320
2024
Q4 		$9.21M Sell
1,661,846
-429,955
-21% -$2.91M 0.08% 260
2024
Q3 		$17.4M Buy
2,091,801
+1,007,896
+93% +$8.29M 0.15% 188
2024
Q2 		$7.38M Hold
1,083,905
– – 0.07% 237
2024
Q1 		$7.11M Sell
1,083,905
-46,147
-4% -$301K 0.07% 261
2023
Q4 		$7.33M Sell
1,130,052
-487,868
-30% -$2.58M 0.09% 251
2023
Q3 		$8.14M Sell
1,617,920
-3,859
-0.2% -$24.5K 0.11% 234
2023
Q2 		$14.2M Sell
1,621,779
-847,733
-34% -$9.88M 0.18% 179
2023
Q1 		$29.2M Buy
2,469,512
+175,136
+8% +$1.67M 0.41% 65
2022
Q4 		$23.4M Buy
2,294,376
+696,447
+44% +$4.64M 0.35% 93
2022
Q3 		$9.41M Buy
1,597,929
+1,387,855
+661% +$5.16M 0.14% 203
2022
Q2 		$521K Buy
210,074
+174,974
+499% +$349K 0.01% 311
2022
Q1 		$104K Buy
+35,100
New +$150K ﹤0.01% 377

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Driehaus Capital Management's TERN Position: Q2 2025 in Review

Driehaus Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 763,486 shares — an estimated $2.11M sold.

Driehaus Capital Management first reported a position in TERN in Q1 2022 and held it in 13 quarters. The position peaked at $29.2M in Q1 2023. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Driehaus Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 763,486 Terns Pharmaceuticals shares in Q2 2025, an estimated $2.11M.
  • Driehaus Capital Management first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • Driehaus Capital Management's Terns Pharmaceuticals position peaked at $29.2M in Q1 2023.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Driehaus Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.